2015
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2015, 109: 416-426. PMID: 25661282, DOI: 10.1016/j.rmed.2014.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAzepinesCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedOrexin Receptor AntagonistsPulmonary Disease, Chronic ObstructiveRespirationSeverity of Illness IndexSleepSleep Aids, PharmaceuticalSpirometryTreatment OutcomeTriazolesUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSleep breathing disordersOrexin receptor antagonistPulmonary diseaseBreathing disordersReceptor antagonistModerate chronic obstructive pulmonary diseaseDay 4Effects of suvorexantModerate airflow limitationRespiratory depressant effectsApnea-hypopnea indexMaximum daily doseClinical research unitTotal sleep timeTreatment of insomniaMean AHICOPD patientsAirflow limitationHypopnea indexDaily doseMean SpO2Spirometry criteriaHypnotic medications
2008
The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease
Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep And Breathing 2008, 13: 79-84. PMID: 18584227, DOI: 10.1007/s11325-008-0196-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultComorbidityCross-Over StudiesDouble-Blind MethodFemaleHumansIndenesMaleOximetryPolysomnographyPulmonary Disease, Chronic ObstructiveReceptors, MelatoninSeverity of Illness IndexSleep Apnea SyndromesSleep Apnea, ObstructiveSleep Initiation and Maintenance DisordersSleep StagesYoung AdultConceptsSevere chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseEffects of ramelteonObstructive pulmonary diseasePulmonary diseaseMean SaO2Respiratory depressant effectsApnea-hypopnea indexPoor sleep qualityTotal sleep timeMelatonin receptor agonistResultsNo significant differencesSignificant differencesAbnormal breathing eventsRamelteon 8Primary endpointAdverse eventsPersistent sleepCrossover studyDepressant effectPolysomnographic monitoringReceptor agonistRespiratory effortInsomnia treatmentSleep quality
2007
Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD
Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep And Breathing 2007, 12: 243-250. PMID: 18060441, DOI: 10.1007/s11325-007-0156-4.Peer-Reviewed Original ResearchConceptsModerate chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseAbnormal breathing eventsSelective MT1/MT2 receptor agonistMT1/MT2 receptor agonistMean apnea-hypopnea indexBreathing eventsEffects of ramelteonMT2 receptor agonistSingle bedtime doseApnea-hypopnea indexObstructive pulmonary diseaseNumber of awakeningsTotal sleep timeMelatonin receptor agonistBedtime dosePlacebo groupAdverse eventsPulmonary diseaseCrossover studyPhysical examinationReceptor agonistSleep efficiencySleep durationSleep time
2004
Factors limiting access to services for sleep apnea patients
Banno K, Kryger MH. Factors limiting access to services for sleep apnea patients. Sleep Medicine Reviews 2004, 8: 253-255. PMID: 15233953, DOI: 10.1016/j.smrv.2004.05.001.Peer-Reviewed Original ResearchCanadaCognition DisordersCystic FibrosisHealth ServicesHealth Services AccessibilityHumansPulmonary Disease, Chronic ObstructiveSleep Apnea Syndromes